Undisclosed saRNA vaccine
Not specified (likely infectious disease)
Commercial (planned from 2024)Active
Key Facts
Indication
Not specified (likely infectious disease)
Phase
Commercial (planned from 2024)
Status
Active
Company
About ARCALIS
Japanese CDMO providing integrated mRNA/LNP development and manufacturing services, with a focus on oncology and vaccine applications.
View full company profile